A recent retrospective study published in CHEST evaluated the effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulator use on pregnancy outcomes in individuals with cystic fibrosis (CF). Conducted across 11 U.S. adult CF centers, including National Jewish Health as one of the two lead sites, the study analyzed data from 307 pregnancies between 2010 and 2021.
Leave A Comment